-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Junctional Epidermolysis Bullosa 1 in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Junctional Epidermolysis Bullosa 1 in Epidermolysis Bullosa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Junctional Epidermolysis Bullosa 1 in Epidermolysis Bullosa Drug...
-
Product Insights
Epidermolysis Bullosa – Drugs In Development, 2023
Global Markets Direct’s, ‘Epidermolysis Bullosa - Drugs In Development, 2023’, provides an overview of the Epidermolysis Bullosa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis Drug Details: Denosumab biosimilar is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imifoplatin in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imifoplatin in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imifoplatin in Basal Cell Carcinoma (Basal Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa in Epidermolysis Bullosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Activate Lamb-3...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa Drug Details Gene therapy is...
-
Product Insights
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa – Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape. Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the...
-
Product Insights
Epidermolysis Bullosa Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Epidermolysis Bullosa Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Epidermolysis Bullosa Clinical trials scenario. This report provides top line data relating to the clinical trials on Epidermolysis Bullosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
-
Track & Monitor
PharmSource – Cell Therapy Market Opportunity for CMOs – 2018 Edition
This PharmSource Trend Report will explore whether the bio/pharma industry is adequately prepared for future cell therapy developments and whether pharma companies and contract manufacturing organizations (CDMOs) Â are making appropriate investments in the capacity and technology to support the coming opportunity. In particular, this Trend Report seeks to achieve the following objectives: